JP2019519227A5 - - Google Patents

Download PDF

Info

Publication number
JP2019519227A5
JP2019519227A5 JP2018561962A JP2018561962A JP2019519227A5 JP 2019519227 A5 JP2019519227 A5 JP 2019519227A5 JP 2018561962 A JP2018561962 A JP 2018561962A JP 2018561962 A JP2018561962 A JP 2018561962A JP 2019519227 A5 JP2019519227 A5 JP 2019519227A5
Authority
JP
Japan
Prior art keywords
fusion protein
protein complex
soluble fusion
soluble
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018561962A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019519227A (ja
JP7037506B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/034656 external-priority patent/WO2017205726A1/en
Publication of JP2019519227A publication Critical patent/JP2019519227A/ja
Publication of JP2019519227A5 publication Critical patent/JP2019519227A5/ja
Application granted granted Critical
Publication of JP7037506B2 publication Critical patent/JP7037506B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018561962A 2016-05-27 2017-05-26 Cd3結合ドメインを有する多量体il-15系分子の構築及び特性評価 Active JP7037506B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662342311P 2016-05-27 2016-05-27
US62/342,311 2016-05-27
US201662397236P 2016-09-20 2016-09-20
US62/397,236 2016-09-20
PCT/US2017/034656 WO2017205726A1 (en) 2016-05-27 2017-05-26 Construction and characterization of multimeric il-15-based molecules with cd3 binding domains

Publications (3)

Publication Number Publication Date
JP2019519227A JP2019519227A (ja) 2019-07-11
JP2019519227A5 true JP2019519227A5 (OSRAM) 2020-06-18
JP7037506B2 JP7037506B2 (ja) 2022-03-16

Family

ID=60412970

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018561962A Active JP7037506B2 (ja) 2016-05-27 2017-05-26 Cd3結合ドメインを有する多量体il-15系分子の構築及び特性評価

Country Status (8)

Country Link
US (1) US10865230B2 (OSRAM)
EP (1) EP3464352B1 (OSRAM)
JP (1) JP7037506B2 (OSRAM)
KR (2) KR20220148306A (OSRAM)
CN (2) CN117362450A (OSRAM)
AU (1) AU2017271593B2 (OSRAM)
CA (1) CA3025343A1 (OSRAM)
WO (1) WO2017205726A1 (OSRAM)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2160401B1 (en) 2007-05-11 2014-09-24 Altor BioScience Corporation Fusion molecules and il-15 variants
US11053299B2 (en) 2010-09-21 2021-07-06 Immunity Bio, Inc. Superkine
CN105017429B (zh) 2010-09-21 2021-04-06 阿尔托生物科学有限公司 多聚体il-15可溶性融合分子与其制造与使用方法
HUE057917T2 (hu) * 2014-01-15 2022-06-28 Kadmon Corp Llc Immunmodulátor szerek
PL3160498T3 (pl) 2014-06-30 2022-02-21 Altor Bioscience Corporation Cząsteczki na bazie IL-15 i sposoby ich zastosowania
CN117362450A (zh) 2016-05-27 2024-01-09 阿尔托生物科学有限公司 具有cd3结合域的基于多聚体il-15的分子的构造和表征
US11472856B2 (en) 2016-06-13 2022-10-18 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function
CA3041310C (en) 2016-10-21 2023-09-05 Altor Bioscience Corporation Multimeric il-15-based molecules
JP7285828B2 (ja) 2017-09-05 2023-06-02 トルク セラピューティクス, インコーポレイテッド 治療用タンパク質組成物ならびにその作製および使用方法
KR20200110326A (ko) * 2017-12-14 2020-09-23 블루버드 바이오, 인코포레이티드. Daric 인터류킨 수용체
TW201938196A (zh) * 2018-01-18 2019-10-01 美商南特生物科學股份有限公司 融合蛋白擴展
CA3090407A1 (en) * 2018-03-01 2019-09-06 Glycotope Gmbh Fusion protein constructs comprising an anti-muc1 antibody and il-15
WO2019191100A1 (en) 2018-03-26 2019-10-03 Altor Bioscience Llc Anti-pdl1, il-15 and tgf-beta receptor combination molecules
WO2019195420A1 (en) 2018-04-04 2019-10-10 Nant Holding IP, LLC Advanced avartar dendritic cells
WO2020037120A1 (en) 2018-08-16 2020-02-20 Nantbio, Inc. Il7-il15 txm compositions and methods
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
KR20230031981A (ko) 2019-05-14 2023-03-07 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
CN114787196A (zh) * 2019-08-29 2022-07-22 南特生物科学公司 修饰的n-810及其方法
EP4045536A4 (en) * 2019-10-16 2023-11-01 Lg Chem, Ltd. Neonatal fc receptor binding affimers
CN111690069B (zh) * 2019-11-13 2022-04-19 中国科学技术大学 一种IL-15/SuIL-15Rα-mFc-γ4复合体蛋白及其构造方法、应用
CN113135996A (zh) * 2019-12-09 2021-07-20 启愈生物技术(上海)有限公司 一种双特异抗体及其应用
IL298999A (en) 2020-06-11 2023-02-01 Provention Bio Inc Methods and compositions for the prevention of type 1 diabetes
WO2022042576A1 (zh) * 2020-08-27 2022-03-03 盛禾(中国)生物制药有限公司 一种多功能融合蛋白及其用途
CN114106195B (zh) * 2020-08-27 2024-09-17 盛禾(中国)生物制药有限公司 一种多功能融合蛋白及其用途
US20230405122A1 (en) * 2020-11-24 2023-12-21 City Of Hope Compositions and uses of psca targeted chimeric antigen receptor modified cells
CN112795543B (zh) * 2021-02-04 2022-09-27 华中农业大学 杂交瘤细胞株及其分泌的抗草鱼IL-15Rα单克隆抗体和应用
TW202241968A (zh) * 2021-04-22 2022-11-01 大陸商廣東菲鵬制藥股份有限公司 雙特異性多功能融合多肽
WO2022253248A1 (zh) * 2021-06-02 2022-12-08 启愈生物技术(上海)有限公司 抗cd3抗体变异体、融合蛋白及应用
JP2024529494A (ja) * 2021-07-30 2024-08-06 クレ バイオテクノロジ (シャンハイ) カンパニー リミテッド 抗原ターゲティング、抗cd16aおよび免疫エフェクター細胞活性化の三機能性融合タンパク質ならびにその応用
CN116143942A (zh) * 2021-09-09 2023-05-23 启愈生物技术(上海)有限公司 抗原靶向、抗cd16a和免疫效应细胞激活三功能融合蛋白及其应用
WO2024197709A1 (zh) * 2023-03-30 2024-10-03 中国科学院深圳先进技术研究院 一种t细胞衔接器及其制备方法和应用
WO2024233299A2 (en) * 2023-05-05 2024-11-14 Board Of Regents, The University Of Texas System Multi-receptor natural killer cells

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
AU5098393A (en) 1992-08-14 1994-03-15 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Recombinant toxin with increased half-life
US5747654A (en) 1993-06-14 1998-05-05 The United States Of America As Represented By The Department Of Health And Human Services Recombinant disulfide-stabilized polypeptide fragments having binding specificity
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5534592A (en) 1995-09-22 1996-07-09 The Goodyear Tire & Rubber Company High performance blend for tire treads
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
US8772451B2 (en) 2003-11-10 2014-07-08 Altor Bioscience Corporation Soluble TCR molecules and methods of use
EP1586585A1 (de) * 2004-04-14 2005-10-19 F. Hoffmann-La Roche Ag Expressionssystem zur Herstellung von IL-15/Fc-Fusionsproteinen und ihre Verwendung
EP2160401B1 (en) 2007-05-11 2014-09-24 Altor BioScience Corporation Fusion molecules and il-15 variants
CN101842117A (zh) * 2007-08-28 2010-09-22 比奥根艾迪克Ma公司 抗igf-1r抗体及其用途
CN105017429B (zh) * 2010-09-21 2021-04-06 阿尔托生物科学有限公司 多聚体il-15可溶性融合分子与其制造与使用方法
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
CN105531374A (zh) * 2013-07-12 2016-04-27 酵活有限公司 双特异性cd3和cd19抗原结合构建体
PL3160498T3 (pl) 2014-06-30 2022-02-21 Altor Bioscience Corporation Cząsteczki na bazie IL-15 i sposoby ich zastosowania
WO2016018920A1 (en) * 2014-07-29 2016-02-04 Admune Therapeutics Llc Il-15 and il-15ralpha heterodimer dose escalation regimens for treating conditions
EP3352779A4 (en) 2015-09-25 2020-02-19 Altor BioScience Corporation INTERLEUKIN-15-SUPERAGONIST FOR SIGNIFICANT REINFORCEMENT OF TRANSPLANT AGAINST TUMOR ACTIVITY
CN117362450A (zh) 2016-05-27 2024-01-09 阿尔托生物科学有限公司 具有cd3结合域的基于多聚体il-15的分子的构造和表征
US20190048055A1 (en) 2017-03-31 2019-02-14 Altor Bioscience Corporation Alt-803 in combination with anti-cd38 antibody for cancer therapies

Similar Documents

Publication Publication Date Title
JP2019519227A5 (OSRAM)
JP2019528077A5 (OSRAM)
JP2017504578A5 (OSRAM)
IL275743A (en) New bispecific format suitable for use in high-through-put screening
JP2019033754A5 (OSRAM)
JP2020074776A5 (OSRAM)
RU2015129640A (ru) Связанные дисульфидом мультивалентные многофункциональные белки, содержащие молекулы гкгс класса 1
RU2015144098A (ru) Четырехвалентные биспецифические антитела
JP2010527919A5 (OSRAM)
EA200870555A1 (ru) Слитые белки, их применение и способы их получения
JP2019516665A5 (OSRAM)
JP5874118B2 (ja) IgA結合性ペプチド及びそれによるIgAの精製
JP2016000731A5 (OSRAM)
JP2018537415A5 (OSRAM)
JP2018522564A5 (OSRAM)
JP2017506882A5 (OSRAM)
JP2018528786A5 (OSRAM)
JP2009524422A5 (OSRAM)
JP2014528696A5 (OSRAM)
JP2014158485A5 (OSRAM)
EA201400046A1 (ru) Удаление клеток-мишеней с помощью циркулирующих вирусспецифических цитотоксических т-клеток с использованием содержащих гкгс класса i комплексов
HRP20130877T1 (hr) Antitijela koja neutraliziraju humani citomegalovirus i njihova primjena
JP2019535315A5 (OSRAM)
RU2018104703A (ru) Опухолеспецифичное антитело против egfr и его применение
JP6985572B2 (ja) 単鎖抗体のスクリーニング方法及び単鎖抗体